StreetInsider.com News Articles

Form SCHEDULE 13G Lexeo Therapeutics, Inc. Filed by: JPMORGAN CHASE & CO

Tue, 13 Oct 2026 13:38:00 -0400

si-local-file:///var/storage/secattach/20261013/27180398.html

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference

Thu, 08 Oct 2026 07:00:00 -0400

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at Chardan’s 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference

Thu, 08 Oct 2026 07:00:00 -0400

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at Chardan’s 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About

Stifel Reiterates Buy Rating on Lexeo Therapeutics (LXEO)

Mon, 05 Oct 2026 05:05:36 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $17.00 price target on Lexeo Therapeutics (NASDAQ: LXEO).
The analyst comments ""We recently hosted the LXEO management team on a NDR and at our cardiometabolic day, including CEO Nolan Townsend, CMO Narinder Bhalla, and CFO Louis Tamayo. We're reiterating our Buy rating, and key takeaways include: (1) on the LX2006 pivotal study in FA-CM: management is confident they can meet a 15% effect-size on LVMI based on the ph 1/2 data and their thoughtful patient selection strategy, (2) a meaningful number of patients have already enrolled in the concurrent NH study that

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

Thu, 01 Oct 2026 09:00:00 -0400

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study

Presentation will include new mFARS subscore analyses providing additional insight into neurologic outcomes following LX2006 treatment

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, announced today its abstract has been accepted to be presented at the International Congress of Parkinson’s Disease

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

Thu, 01 Oct 2026 09:00:00 -0400

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study

Presentation will include new mFARS subscore analyses providing additional insight into neurologic outcomes following LX2006 treatment

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, announced today its abstract has been accepted to be presented at the International Congress of Parkinson’s Disease

Form 8-K Lexeo Therapeutics, Inc. For: Sep 29

Tue, 29 Sep 2026 16:21:00 -0400
si-local-file:///var/storage/secattach/20260929/27122748.html

Form 4 Lexeo Therapeutics, Inc. For: Sep 24 Filed by: Townsend Richard Nolan

Mon, 28 Sep 2026 17:15:00 -0400
si-local-file:///var/storage/secattach/20260928/27115496.html

Form 4 Lexeo Therapeutics, Inc. For: Sep 24 Filed by: Tamayo Louis Edward

Mon, 28 Sep 2026 17:15:00 -0400
si-local-file:///var/storage/secattach/20260928/27115498.html

Form 4 Lexeo Therapeutics, Inc. For: Sep 24 Filed by: Otero Jose Manuel

Mon, 28 Sep 2026 17:15:00 -0400
si-local-file:///var/storage/secattach/20260928/27115499.html

Form 4 Lexeo Therapeutics, Inc. For: Sep 24 Filed by: Bhalla Narinder Pal

Mon, 28 Sep 2026 17:15:00 -0400
si-local-file:///var/storage/secattach/20260928/27115500.html

Apertura Gene Therapy grants Lexeo access to BBB-crossing capsid

Wed, 23 Sep 2026 08:02:21 -0400

Apertura Gene Therapy has agreed to provide Lexeo Therapeutics (NASDAQ: LXEO) access to its TfR1 CapX™ capsid technology for use in a program designed to treat Friedreich ataxia, according to a press release.
TfR1 CapX is an intravenously delivered AAV capsid designed to target human transferrin receptor 1 and cross the blood-brain barrier. Lexeo said the agreement expands its options as it evaluates approaches to address Friedreich ataxia, including a potentially less invasive route of administration to the central nervous system alongside its existing LX2006 program.
Friedreich ataxia is a genetic, progressive, degenerative multi-system disorder with a prevalence of approximately 1 in

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

Wed, 23 Sep 2026 08:00:00 -0400

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia. Apertura's TfR1 CapX is an intravenously delivered AAV capsid designed to target human transferrin receptor 1 (hTfR1)

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

Wed, 23 Sep 2026 08:00:00 -0400

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia. Apertura's TfR1 CapX is an intravenously delivered AAV capsid designed to target human transferrin receptor 1 (hTfR1)

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Wed, 23 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Wed, 23 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

Baird on Lexeo Therapeutics (LXEO): 'Incrementally positive on deal'

Tue, 22 Sep 2026 09:42:31 -0400

Baird analyst Brian Skorney reiterated an Outperform rating and $28.00 price target on Lexeo Therapeutics (NASDAQ: LXEO).
The analyst comments "Incrementally positive on deal. The announced agreement to acquire Mantle Therapeutics (private) and collaborate with Cornell Med, Aperture and Vivet brings in four unique assets focused on FA, and several avenues to enhance the opportunity for LX2006 beyond cardiomyopathy. At a little over $20M in combined upfront/milestones, we think it's a very reasonable value to bring in a number of products that offer potential to expand on LX2006's cardiac focus, with muscular and CNS targeted mechanisms."
For an analyst ratings summary and

Raymond James Reiterates Strong Buy Rating on Lexeo Therapeutics (LXEO)

Tue, 22 Sep 2026 08:08:58 -0400

Raymond James analyst Christopher Raymond reiterated a Strong Buy rating and $24.00 price target on Lexeo Therapeutics (NASDAQ: LXEO).
The analyst comments "We remain Strong Buy rated on LXEO shares after the company announced the acquisition of Mantle Therapeutics and the initiation of additional research collaborations to further advance Lexeo’s capabilities to treat Friedrich’s ataxia (FA). On the Mantle deal specifically, we see this as a cost-effective move that both provides technological diversification and underscores the company’s commitment to FA. Although we were not aware of Mantle (which has been operating in stealth) and believe most investors were not either, Mantle’s

Form 8-K Lexeo Therapeutics, Inc. For: Sep 16

Tue, 22 Sep 2026 07:09:00 -0400
si-local-file:///var/storage/secattach/20260922/27087468.html

Lexeo to acquire Mantle Therapeutics for up to $21.3M in FA push

Tue, 22 Sep 2026 07:01:06 -0400

Lexeo Therapeutics (Nasdaq: LXEO) has signed a definitive agreement to acquire Mantle Therapeutics Inc., a private clinical-stage company focused on Friedreich ataxia (FA) therapies, for $8.3 million in upfront consideration consisting of cash and equity, with up to $13.0 million in additional milestone-based payments, bringing total potential consideration to $21.3 million.

The deal, signed Sept. 16, 2026, is expected to close in the third quarter of 2026, subject to customary closing conditions. The acquisition adds four programs to Lexeo's portfolio: LX3010, an oral combination therapy in clinical stage that showed an approximately six-point improvement in mFARS scores at 16 weeks and

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Tue, 22 Sep 2026 07:00:00 -0400

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain

Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease

SUNRISE-FA 2 pivotal study continues enrollment and remains the company’s top priority development program; topline data on track for 2H 2027

Disciplined capital allocation supports these strategic initiatives while maintaining cash runway into 2028

Company to host webcast today at 8:00 AM ET

NEW YORK, Sept. 22,

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Tue, 22 Sep 2026 07:00:00 -0400

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain

Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease

SUNRISE-FA 2 pivotal study continues enrollment and remains the company’s top priority development program; topline data on track for 2H 2027

Disciplined capital allocation supports these strategic initiatives while maintaining cash runway into 2028

Company to host webcast today at 8:00 AM ET

NEW YORK, Sept. 22,

Form 4 Lexeo Therapeutics, Inc. For: Aug 18 Filed by: Otero Jose Manuel

Wed, 19 Aug 2026 17:00:00 -0400
si-local-file:///var/storage/secattach/20260819/26950934.html

Form 4 Lexeo Therapeutics, Inc. For: Aug 18 Filed by: Otero Jose Manuel

Wed, 19 Aug 2026 17:00:00 -0400
si-local-file:///var/storage/secattach/20260819/26950934.html

Form 4 Lexeo Therapeutics, Inc. For: Aug 18 Filed by: Townsend Richard Nolan

Wed, 19 Aug 2026 17:00:00 -0400
si-local-file:///var/storage/secattach/20260819/26950936.html